Astrazeneca Plc Adr Stock Revenue
| 0A4J Stock | 63.80 1.80 2.74% |
AstraZeneca PLC ADR fundamentals help investors to digest information that contributes to AstraZeneca PLC's financial success or failures. It also enables traders to predict the movement of AstraZeneca Stock. The fundamental analysis module provides a way to measure AstraZeneca PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AstraZeneca PLC stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 30.6 B | 26.1 B |
AstraZeneca | Revenue |
AstraZeneca PLC ADR Company Revenue Analysis
AstraZeneca PLC's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current AstraZeneca PLC Revenue | 51.21 B |
Most of AstraZeneca PLC's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AstraZeneca PLC ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of AstraZeneca
Projected quarterly revenue analysis of AstraZeneca PLC ADR provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of AstraZeneca PLC match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in AstraZeneca PLC's stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
AstraZeneca Total Revenue
Total Revenue |
|
Based on the latest financial disclosure, AstraZeneca PLC ADR reported 51.21 B of revenue. This is much higher than that of the Commercial Services & Supplies sector and significantly higher than that of the Industrials industry. The revenue for all United Kingdom stocks is significantly lower than that of the firm.
AstraZeneca Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AstraZeneca PLC's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AstraZeneca PLC could also be used in its relative valuation, which is a method of valuing AstraZeneca PLC by comparing valuation metrics of similar companies.AstraZeneca PLC is currently under evaluation in revenue category among its peers.
AstraZeneca Fundamentals
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.085 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 128.51 B | ||||
| Shares Owned By Institutions | 16.75 % | ||||
| Revenue | 51.21 B | ||||
| Gross Profit | 35.73 B | ||||
| EBITDA | 18.39 B | ||||
| Net Income | 5.96 B | ||||
| Book Value Per Share | 26.27 X | ||||
| Cash Flow From Operations | 9.81 B | ||||
| Earnings Per Share | (0.36) X | ||||
| Target Price | 71.9 | ||||
| Number Of Employees | 89.9 K | ||||
| Beta | 0.18 | ||||
| Retained Earnings | 3.12 B | ||||
| Annual Yield | 0.0002 % | ||||
| Last Dividend Paid | 2.97 |
About AstraZeneca PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AstraZeneca PLC ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AstraZeneca PLC ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for AstraZeneca Stock Analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.